CN110122881A - A kind of alimentation composition promoting child height development - Google Patents
A kind of alimentation composition promoting child height development Download PDFInfo
- Publication number
- CN110122881A CN110122881A CN201910384706.5A CN201910384706A CN110122881A CN 110122881 A CN110122881 A CN 110122881A CN 201910384706 A CN201910384706 A CN 201910384706A CN 110122881 A CN110122881 A CN 110122881A
- Authority
- CN
- China
- Prior art keywords
- group
- weight
- grouped
- following parts
- alimentation composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000011161 development Methods 0.000 title claims abstract description 15
- 230000001737 promoting effect Effects 0.000 title claims description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 44
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 37
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 34
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 34
- 239000000122 growth hormone Substances 0.000 claims abstract description 34
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 235000016709 nutrition Nutrition 0.000 claims abstract description 24
- 230000035764 nutrition Effects 0.000 claims abstract description 24
- 230000037322 slow-wave sleep Effects 0.000 claims abstract description 21
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 15
- 239000011707 mineral Substances 0.000 claims abstract description 15
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019742 Vitamins premix Nutrition 0.000 claims abstract description 11
- 235000005911 diet Nutrition 0.000 claims abstract description 11
- 230000037213 diet Effects 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 11
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 10
- 229920001202 Inulin Polymers 0.000 claims abstract description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 7
- 229940029339 inulin Drugs 0.000 claims abstract description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000004471 Glycine Substances 0.000 claims abstract description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 6
- 229930064664 L-arginine Natural products 0.000 claims abstract description 6
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 6
- 229940000635 beta-alanine Drugs 0.000 claims abstract description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 6
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 46
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- 235000001465 calcium Nutrition 0.000 claims description 18
- 235000013336 milk Nutrition 0.000 claims description 15
- 239000008267 milk Substances 0.000 claims description 15
- 210000004080 milk Anatomy 0.000 claims description 15
- 235000010755 mineral Nutrition 0.000 claims description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 5
- 239000001354 calcium citrate Substances 0.000 claims description 5
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 5
- 239000011666 cyanocobalamin Substances 0.000 claims description 5
- 229960002104 cyanocobalamin Drugs 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 5
- 239000001095 magnesium carbonate Substances 0.000 claims description 5
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 5
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 5
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 5
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 5
- 235000005282 vitamin D3 Nutrition 0.000 claims description 5
- 239000011647 vitamin D3 Substances 0.000 claims description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
- 229940021056 vitamin d3 Drugs 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 4
- 235000019743 Choline chloride Nutrition 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229960004874 choline bitartrate Drugs 0.000 claims description 4
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 4
- 229960003178 choline chloride Drugs 0.000 claims description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 4
- 239000011790 ferrous sulphate Substances 0.000 claims description 4
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 229940099596 manganese sulfate Drugs 0.000 claims description 4
- 239000011702 manganese sulphate Substances 0.000 claims description 4
- 235000007079 manganese sulphate Nutrition 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- UGWKCNDTYUOTQZ-UHFFFAOYSA-N copper;sulfuric acid Chemical compound [Cu].OS(O)(=O)=O UGWKCNDTYUOTQZ-UHFFFAOYSA-N 0.000 claims 1
- KNLQKHUBPCXPQD-UHFFFAOYSA-N manganese;sulfuric acid Chemical compound [Mn].OS(O)(=O)=O KNLQKHUBPCXPQD-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 235000012711 vitamin K3 Nutrition 0.000 claims 1
- 239000011652 vitamin K3 Substances 0.000 claims 1
- 229940041603 vitamin k 3 Drugs 0.000 claims 1
- 230000028327 secretion Effects 0.000 abstract description 9
- 235000013350 formula milk Nutrition 0.000 abstract description 5
- 235000020251 goat milk Nutrition 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 239000006071 cream Substances 0.000 description 17
- 241001494479 Pecora Species 0.000 description 16
- 208000006386 Bone Resorption Diseases 0.000 description 15
- 230000024279 bone resorption Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000005862 Whey Substances 0.000 description 13
- 102000007544 Whey Proteins Human genes 0.000 description 13
- 108010046377 Whey Proteins Proteins 0.000 description 13
- 239000006188 syrup Substances 0.000 description 12
- 235000020357 syrup Nutrition 0.000 description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 description 12
- 239000008158 vegetable oil Substances 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 230000000996 additive effect Effects 0.000 description 11
- 238000005238 degreasing Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 241000219095 Vitis Species 0.000 description 9
- 235000009754 Vitis X bourquina Nutrition 0.000 description 9
- 235000012333 Vitis X labruscana Nutrition 0.000 description 9
- 235000014787 Vitis vinifera Nutrition 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000012010 growth Effects 0.000 description 6
- 230000037182 bone density Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000020254 sheep milk Nutrition 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101000783348 Naja atra Cytotoxin 1 Proteins 0.000 description 2
- 101000761722 Naja kaouthia Cytotoxin 1 Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 235000005523 excessive nutrition Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LFDGRWDETVOGDT-UHFFFAOYSA-N 1h-pyrrole;hydrochloride Chemical compound Cl.C=1C=CNC=1 LFDGRWDETVOGDT-UHFFFAOYSA-N 0.000 description 1
- JXPHLUCMHXXHEJ-UHFFFAOYSA-N 2-(aminomethyl)-4-bromoaniline Chemical compound NCC1=CC(Br)=CC=C1N JXPHLUCMHXXHEJ-UHFFFAOYSA-N 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 101000911775 Mus musculus Hsc70-interacting protein Proteins 0.000 description 1
- 101000836210 Mus musculus Somatotropin Proteins 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940003871 calcium ion Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- FYPVXEILSNEKOO-UHFFFAOYSA-L calcium;butanoate Chemical compound [Ca+2].CCCC([O-])=O.CCCC([O-])=O FYPVXEILSNEKOO-UHFFFAOYSA-L 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000002391 femur head Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- -1 phosphatide Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- RWMKSKOZLCXHOK-UHFFFAOYSA-M potassium;butanoate Chemical compound [K+].CCCC([O-])=O RWMKSKOZLCXHOK-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of alimentation compositions of promotion child height development, are grouped as by the group of following parts by weight: growth hormone promotor 12-20, slow wave sleep promotor 5-9, bone steady-state adjustment agent 47-71, nutrition fortifier 7-19；Wherein, the growth hormone promotor is grouped as by the group of following parts by weight: L-arginine 4-6, Beta-alanine 2-4, L-Glutamine 3-4, L- glycine 3-5；The slow wave sleep promotor is grouped as by the group of following parts by weight: γ-aminobutyric acid 1-2, L-Trp 1.5-2.5；The bone steady-state adjustment agent is grouped as by the group of following parts by weight: diet butyric acid 5-9, prebiotics 45-55, inulin 0.5-1.5；The nutrition fortifier is grouped as by the group of following parts by weight: mineral substance premix 5-15, vitamin premix 2-3.5.It can be added in formula milk, while meeting needed for child nutrition, promote growth hormone secretion, various dimensions help child height development.
Description
Technical field
The invention belongs to food technology fields, and in particular to a kind of alimentation composition for promoting child height development.
Background technique
Bai Chunli discloses a kind of formula milk of help child height development in Chinese patent 201811388303.X
And production method, comprising raw milk or whole milk powder, desalted whey powder, skimmed milk power, corn syrup solid (or maltodextrin),
PURE WHEY, crystal diabetin, vegetable oil, oligofructose, anhydrous butter oil, galactooligosaccharide, docosahexaenoic acid, colostrum
Powder, newborn mineral salt, hydrolysis yolk powder, lactoferrin, phosphatide, vitamin A, vitamin D, vitamin E, vitamin K, vitamin
The ingredients such as B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, magnesium, calcium, iron, zinc, selenium.The patent nutrition-allocated proportion is equal
Weighing apparatus, while certain nutrients (such as hydrolysis yolk powder, calcium, zinc) are enhanced to help child height to develop.However, influencing children
Height growth it is many because being known as, other than guaranteeing the nutrition supply of science, growth hormone itself also develops child height
It plays a leading role, is not added with growth hormone promotor and slow wave sleep promotor in existing children's milk powder, mainly relies on
The strong bone of nutrition fortifier and good protein help growth and development, and the present invention is a kind of alimentation composition, can be added to
In formula milk, while meeting needed for child nutrition, promote growth hormone secretion.Various dimensions help child height development.
Summary of the invention
The present invention is directed to overcome the deficiencies of the prior art and provide a kind of alimentation composition of promotion child height development.
In order to achieve the above object, technical solution provided by the invention are as follows:
The alimentation composition for promoting child height development is grouped as by the group of following parts by weight:
Growth hormone promotor 12-20, slow wave sleep promotor 5-9, bone steady-state adjustment agent 47-71, nutrition fortifier
7—19；
Wherein, the growth hormone promotor is grouped as by the group of following parts by weight: L-arginine 4-6, Beta-alanine
2-4, L-Glutamine 3-4, L- glycine 3-5；
The slow wave sleep promotor is grouped as by the group of following parts by weight: γ-aminobutyric acid 1-2, L-Trp
1.5—2.5；
The bone steady-state adjustment agent is grouped as by the group of following parts by weight: diet butyric acid 5-9, prebiotics 45-55, inulin
0.5—1.5；
The nutrition fortifier is grouped as by the group of following parts by weight: mineral substance premix 5-15, vitamin premix
2—3.5。
Preferably, the mineral substance premix is grouped as by the group of following parts by weight: calcium citrate 140-145, magnesium carbonate
10-15, ferrous sulfate 2-3, magnesium chloride 2-3, zinc sulfate 2-3, copper sulphate 0.08-0.09, manganese sulfate 0.2-0.3；Institute
Vitamin premix is stated to be grouped as by the group of following parts by weight: L-AA 35-45, L-AA salt 20-30, naturally
Vitamin E 6-7, niacinamide 2-3, D-VB5 calcium 2-3, riboflavin 0.9-1, thiamine hydrochloride 0.3-0.4, hydrochloric acid pyrrole are trembled
Alcohol 0.2-0.3, axerophtholum aceticum 0.5-0.6, folic acid 0.05-0.09, phytondione 0.03-0.07, biotin
0.008-0.012, Vitamin D3 0.008-0.012, cyanocobalamin 0.008-0.012, choline chloride 28-33, hydrogen tartrate
Choline 200-205.
Preferably, the growth hormone promotor is grouped as by the group of following parts by weight: L-arginine 5, Beta-alanine 3,
L-Glutamine 3.5, L- glycine 4；The slow wave sleep promotor is grouped as by the group of following parts by weight: γ-aminobutyric acid
1.5, L-Trp 2；The bone steady-state adjustment agent is grouped as by the group of following parts by weight: diet butyric acid 7, prebiotics 50, inulin
1；The nutrition fortifier is grouped as by the group of following parts by weight: mineral substance premix 5-15, vitamin premix 2-3.5.
Preferably, the mineral substance premix is grouped as by the group of following parts by weight: calcium citrate 143, magnesium carbonate 12, sulphur
Sour ferrous iron 2.8, magnesium chloride 2.5, zinc sulfate 2.3, copper sulphate 0.085, manganese sulfate 0.22；The vitamin premix by weighing as follows
The group of amount part is grouped as: L-AA 40, L-AA salt 26, natural VE 6.8, niacinamide 2.4, D-VB5 calcium
2.2, riboflavin 0.96, thiamine hydrochloride 0.32, puridoxine hydrochloride 0.27, axerophtholum aceticum 0.55, folic acid 0.07, plant first
Naphthoquinones 0.05, biotin 0.01, Vitamin D3 0.01, cyanocobalamin 0.01, choline chloride 31.5, choline bitartrate 204.
Preferably, the prebiotics are at least one of FOS and GOS.
Preferably, the diet butyric acid is butyric acid, butyrate, the alkyl comprising butyric acid and/or glyceride, butyric acid-ring paste
At least one of smart complex compound.
When using the alimentation composition, alimentation composition is added in modulation milk powder, the alimentation composition is being adjusted
Weight percent in milk powder processed is 7-10%.
The invention will be further described below:
In alimentation composition of the present invention, growth hormone promotor can directly facilitate the secretion of growth hormone, to draw
Play bone growth.Since growth hormone secretion vigorous period is in the slow wave sleep stage, slow wave sleep promotor can extend slowly
Wave sleeping time promotes the secretion of growth hormone indirectly.The absorptivity of calcium can be improved in bone steady-state adjustment agent, inhibits bone resorption, increases
Strong bone density.Wherein diet butyric acid can be there are many presentation mode: 1. butyric acid 2. butyrate (sodium butyrate, potassium butyrate, calcium butyrate or
Magnesium butyrate) the 3. alkyl comprising butyric acid and/or glyceride 4. butyric acid-cyclodextrin-complex.Studies have shown that diet butyric acid can be with
Inhibit osteoclast to generate, reduce bone resorption, prevent bone-loss, increases bon e formation.Prebiotics and inulin belong to endogenous can
The component for generating endogenous butyric acid can stimulate and generate butyric acid and other short chain fatty acids in enteron aisle, to be acidified enteric cavity, increase mine
Solubility of the substance in enteron aisle, the expansion of sorbent surface increase the calcium pickup of long cell.Due to certain in ordinary modulation milk powder
Microelement and vitamin content are insufficient, and addition nutrition fortifier can promote its nutritive value with the nutrition of equalized modulation milk powder.
Alimentation composition of the present invention promotes height growth in terms of helping growth hormone secretion, adjusting bone stable state,
Compared with the existing alimentation composition or milk powder for promoting skeleton development, the biology for improving calcium is not only helped containing bone steady-state adjustment agent
Utilization rate inhibits bone resorption, enhancing bone density, also includes growth hormone promotor and slow wave sleep promotor, this two groups of ingredients
It can promote the secretion growth hormone that organism is spontaneous, so that the epiphyseal cartilage at bone both ends is made constantly to divide out cartilage cell,
These cartilage cells get off to be formed by calcified deposits the growth of bone.
In short, the alimentation composition of the present invention for promoting child height development, can be added in formula milk, full
While needed for sufficient child nutrition, promote growth hormone secretion, various dimensions help child height development.
Detailed description of the invention
Fig. 1 is that each group Mice Body is long (cm)；
Fig. 2 is each group mouse CTX-I horizontal (ng/mL)；
Fig. 3 is the auxin (ng/mL) in each group mice serum；
Fig. 4 is each group bone mineral density in mice (g/cm2)；
Fig. 5 is each group mouse blood calcium concentration (ng/dL).
Specific embodiment
Each tested group of component proportion (parts by weight) (table 1):
Blank group (ordinary modulation sheep milk powder): sheep PURE WHEY 6, cream is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Sugar 22, vegetable oil 14, glucose syrup solids 1.
Control group 1: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1, growth hormone promotor 1.8.
Control group 2: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1, slow wave sleep promotor 0.7.
Control group 3: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1, bone steady-state adjustment agent 7.
Control group 4: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1, nutrition fortifier 1.9.
Control group 5: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1, growth hormone promotor 1.5, bone steady-state adjustment agent 6.5.
Control group 6: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1, growth hormone promotor 1.4, bone steady-state adjustment agent 6, slow wave sleep promotor 0.6.
Experimental group 1: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1 ,+alimentation composition, weight percent of the alimentation composition in ordinary modulation milk powder are 5%.
Experimental group 2: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1 ,+alimentation composition, weight percent of the alimentation composition in ordinary modulation milk powder are 9%.
Experimental group 3: sheep PURE WHEY 6, lactose 22, vegetable oil 14, Portugal is concentrated in degreasing goat milk powder 43, full-cream goat milk powder 5
Grape syrup solid 1 ,+alimentation composition, weight percent of the alimentation composition in ordinary modulation milk powder are 12%.It is described
The alimentation composition of child height development is promoted to be grouped as by the group of following parts by weight:
Growth hormone promotor 12-20, slow wave sleep promotor 5-9, bone steady-state adjustment agent 47-71, nutrition fortifier
7—19；
Wherein, the growth hormone promotor is grouped as by the group of following parts by weight: L-arginine 5, Beta-alanine 3, L-
Glutamine 3.5, L- glycine 4；The slow wave sleep promotor is grouped as by the group of following parts by weight: γ-aminobutyric acid
1.5, L-Trp 2；The bone steady-state adjustment agent is grouped as by the group of following parts by weight: diet butyric acid 7, prebiotics 50, inulin
1；The nutrition fortifier is grouped as by the group of following parts by weight: mineral substance premix 5-15, vitamin premix 2-3.5；
The mineral substance premix is grouped as by the group of following parts by weight: calcium citrate 143, magnesium carbonate 12, ferrous sulfate 2.8, chlorination
Magnesium 2.5, zinc sulfate 2.3, copper sulphate 0.085, manganese sulfate 0.22；The vitamin premix is grouped by the group of following parts by weight
At: L-AA 40, L-AA salt 26, natural VE 6.8, niacinamide 2.4, D-VB5 calcium 2.2, riboflavin
0.96, thiamine hydrochloride 0.32, puridoxine hydrochloride 0.27, axerophtholum aceticum 0.55, folic acid 0.07, phytondione 0.05,
Biotin 0.01, Vitamin D3 0.01, cyanocobalamin 0.01, choline chloride 31.5, choline bitartrate 204.The prebiotics are
At least one of FOS and GOS.The diet butyric acid is butyric acid, butyrate, the alkyl comprising butyric acid and/or glyceride, fourth
At least one of acid-cyclodextrin-complex.
Preparation process:
Wet processing
(1) sheep cream standardizes:
Raw sheep cream pre-sterilizing: after the raw sheep cream acceptance(check) of raw material, progress pasteurize, 80~85 DEG C, 15~30s.
Sheep cream standardization: by the sheep cream of predetermined weight proportion, degreasing goat milk powder, concentration sheep PURE WHEY, vegetable oil, cream
Sugar, glucose syrup are uniformly mixed, and obtain mixed solution, are put into temporary storage tank and are kept in；
(2) high-pressure homogeneous: homogeneous, homogenization pressure 12-15Mpa are carried out in high pressure homogenizer；
(3) it sterilizes: 92-96 DEG C, 1min；
(4) it is concentrated: being concentrated by evaporation；
(5) it sterilizes: re-pasteurization, 72-75 DEG C, 1min；
(6) homogeneous: second homogenate mixing, homogenization pressure 12-15Mpa；
(7) dry: spray drying obtains ordinary modulation sheep milk powder.
Dry process
(1) dry-mixed: to add the alimentation composition in ordinary modulation sheep milk powder；
(2) it vacuumizes, is filled with inert gas and nitrogen, pack.
Experimental method: this research use male C57BL/6 mouse, 6 week old, 100, adaptable fed after a week, at random
It is divided into 3 groups, every group 10, feeds each group mouse according to following table, the feeding daily 5g/ of dosage only, is fed 5 weeks, carries out index of correlation
Detection.
Table 1
Test index:
1) growth period Mice Body is long: anesthesia blank group, control group, and the mouse of experimental group it is long to measure its body with ruler, from the beginning
Portion's top is that body is long to mouse hip circumference junction, is accurate to 1mm.
2) bone resorption reduces degree (CTX-I marks analyte detection): intraperitoneal injection of anesthesia mouse, cardiac puncture draw appropriate blood
Liquid injects in 1.5mlEP pipe.4 DEG C of centrifuge 3000r/min, 20min are centrifuged 2 times, are taken supernatant every time, are obtained serum specimen,
Osteoclastic marker is detected according to ELISA kit specification.
3) growth hormone in serum: each group mouse assay body is long with after Bone resorption markers, under narcosis, utilizes
Eyeball blood taking method takes mouse blood, at room temperature to blood natural coagulation 20min, 20min is centrifuged with 3000r/min, in collection
Clear liquid, it is horizontal using ELISA kit measurement GH.
4) bone mineral density in mice: rapidly being put to death mouse with spondylexarthrosis method, removes mouse bilateral femur, pays attention to keeping femur
Head integrality after rejecting the tissue such as its meat, fascia, is wrapped up with the gauze for being soaked with physiological saline, is saved in -20 DEG C of refrigerators, used
In detection femoral bmd.Bone mineral density is detected with dual-energy x-ray borne densitometers.
5) blood calcium concentration: after taking blood using eyeball blood taking method to mouse, blood sample is collected with the centrifuge tube of 2ml, and 4
After 4000r/min is centrifuged 15min at DEG C, saved in the serum of acquisition and -25 DEG C of refrigerators, blood calcium catalyst is referring to reagent in serum
Box illustrates to be operated.
Experimental result (Fig. 1 to Fig. 5):
Fig. 1 shows the ordinary modulation sheep milk powder (experimental group 1) for being added to 9% alimentation composition and control group, blank group phase
Than increase long for the body of mouse has apparent facilitation, and experimental group 2 (alimentation composition additive amount 5%) is long for body
Increase effect of the effect not as good as most of control group, illustrates that the addition of the low dosage alimentation composition cannot generate good effect
Fruit, compared with experimental group 1 (alimentation composition additive amount 9%), Mice Body is long to be increased experimental group 3 (alimentation composition additive amount 12%)
Long effect does not increase further, this may be that nutrient excess causes mouse generation not tolerate caused by reaction.
In conclusion having synergistic effect in terms of promoting the long growth of Mice Body between the alimentation composition each component, and add
Dosage can be only achieved ideal effect in recommended range.
Bone resorption (Boneresorption) refers to that under lower stress level, the volume and density of bone tissue are gradually sent out
Give birth to the physiological behavior of drop.Bone resorption is the critical function for constituting bone remoulding, embodies bone tissue to the adaptation energy of mechanical environment
Power.Abnormal bone remoulding phenomenon may result in osteoporosis symptoms, to become the inducement of fracture.Bone turnover markers
It not only can reflect the dynamic equilibrium situation of bone resorption and bon e formation, but also earlier than the change of bone density, to osteoporosis
Early diagnosis, the antidiastole of metabolic bone disease, osteosporosis resistant medicament efficacy determination have important value.
Type I collagen terminal peptide is the non-helical region peptide chain of Type I collagen terminal chiasma connection, is osteoclast in bone resorption
It degrades the specific product of generation, is deposited in the form of amino terminal peptide (NTX)/carboxy terminal peptide (CTX) in blood in the process
It can intuitively reflect bone resorption situation.
Fig. 2, which shows the milk powder containing bone steady-state adjustment agent, to be had the function of inhibiting bone resorption, but contains bone stable state simultaneously
The milk powder of regulator and nutrition fortifier inhibits bone resorption more significant (experimental group 1, experimental group 2, experimental group 3).This may
It is due to the calcium and vitamin D (D-VB5 calcium) in the agent of bone steady-state adjustment and nutrition fortifier, vitamin K1 (phytondione)
Synergistic effect is produced, inhibits bone resorption jointly.The inhibition bone resorption of experimental group 2 (alimentation composition additive amount 5%) is inferior
In experimental group 1 (alimentation composition additive amount 9%) and experimental group 3 (alimentation composition additive amount 12%), illustrate alimentation composition
Dosage is not up to effect, and the effect of experimental group 3 is not better than experimental group 1, illustrates that effect cannot be obviously improved by continuing increased dosage amount
Fruit, therefore there is no practical significance.
Fig. 3 shows the mouse of all control groups and experimental group compared to the blank group, and intracorporal growth hormone has increase, says
It is bright in terms of influencing mouse growth hormone, add growth hormone promotor, slow wave sleep promotor, the agent of bone steady-state adjustment, nutrition
Any one or a few ingredient in hardening agent, all effect than not adding are good.
Growth hormone promotor and the other mouse of slow wave sleep promotor group (control group 1, control are added in control group
Group 2, control group 5, control group 6) growth hormone than do not add group (control group 3, control group 4) height, illustrate growth hormone
Promotor and slow wave sleep promotor play an important role to the secretion of Mice Body inner growth hormone.
The effect of experimental group 1 (alimentation composition additive amount 9%) better than experimental group 1 (alimentation composition additive amount 5%) and
Experimental group 3 (alimentation composition additive amount 12%) illustrates that alimentation composition additive capacity deficiency will not generate ideal effect, and adds
Add dosage excessive, facilitation effect will not be obviously improved, declined instead, this may be since the nutrients of large dosage causes
Mouse body burden, produces adverse effect to metabolism.
Fig. 4 shows that bone density can reflect the strength of bone, as seen from the above table, nutrition is added in control group
Hardening agent and the growth hormone of the other mouse of bone steady-state adjustment agent group (control group 3, control group 4, control group 5, control group 6) than
Group (control group 1, control group 2) height is not added, and the bone density of 3 mouse of experimental group 1 and experimental group is significantly higher than other groups, explanation
Growth hormone promotor, slow wave sleep promotor and nutrition fortifier and bone steady-state adjustment agent have synergistic effect, and help enhances bone
Bone is strong.The effect of the strong bone of experimental group 3 is not significantly better than experimental group 1, and excessive nutrition will lead to mouse body and bear
Load, therefore nonsensical increase additive amount.
Fig. 5 is it is found that the agent of bone steady-state adjustment and nutrition fortifier help to promote blood calcium concentration, and the agent of bone steady-state adjustment and life
Long hormone regulator/slow wave sleep promotes machine joint, can strengthen blood calcium concentration raising, be more conducive to Calcium-ion absorption, increase
The alimentation composition of dosage does not promote blood calcium concentration further, and excessive nutrition will lead to mouse body burden, therefore does not build
Alimentation composition is excessively used in view.
In conclusion adding this alimentation composition according to 7-10% ratio has obviously into regular convention formula goat milk powder
Raising height effect.
Claims (8)
1. a kind of alimentation composition for promoting child height development, which is characterized in that the alimentation composition is by following parts by weight
Group be grouped as:
Growth hormone promotor 12-20, slow wave sleep promotor 5-9, bone steady-state adjustment agent 47-71, nutrition fortifier 7-
19；
Wherein, the growth hormone promotor is grouped as by the group of following parts by weight: L-arginine 4-6, Beta-alanine 2-4,
L-Glutamine 3-4, L- glycine 3-5；
The slow wave sleep promotor is grouped as by the group of following parts by weight: γ-aminobutyric acid 1-2, L-Trp 1.5-
2.5；
The bone steady-state adjustment agent is grouped as by the group of following parts by weight: diet butyric acid 5-9, prebiotics 45-55, inulin
0.5—1.5；
The nutrition fortifier is grouped as by the group of following parts by weight: mineral substance premix 5-15, vitamin premix 2-
3.5。
2. alimentation composition as described in claim 1, which is characterized in that the mineral substance premix by following parts by weight group
It is grouped as: calcium citrate 140-145, magnesium carbonate 10-15, ferrous sulfate 2-3, magnesium chloride 2-3, zinc sulfate 2-3, sulfuric acid
Copper 0.08-0.09, manganese sulfate 0.2-0.3；The vitamin premix is grouped as by the group of following parts by weight: L-AA
35-45, L-AA salt 20-30, natural VE 6-7, niacinamide 2-3, D-VB5 calcium 2-3, riboflavin 0.9-
1, thiamine hydrochloride 0.3-0.4, puridoxine hydrochloride 0.2-0.3, axerophtholum aceticum 0.5-0.6, folic acid 0.05-0.09, plant
Object menadione 0.03-0.07, biotin 0.008-0.012, Vitamin D3 0.008-0.012, cyanocobalamin 0.008-
0.012, choline chloride 28-33, choline bitartrate 200-205.
3. alimentation composition as claimed in claim 2, which is characterized in that the growth hormone promotor is by following parts by weight
Group is grouped as: L-arginine 5, Beta-alanine 3, L-Glutamine 3.5, L- glycine 4；The slow wave sleep promotor is by as follows
The group of parts by weight is grouped as: γ-aminobutyric acid 1.5, L-Trp 2；The bone steady-state adjustment agent by following parts by weight component
Composition: diet butyric acid 7, prebiotics 50, inulin 1；The nutrition fortifier is grouped as by the group of following parts by weight: minerals premix
Material 5-15, vitamin premix 2-3.5.
4. alimentation composition as claimed in claim 3, which is characterized in that the mineral substance premix by following parts by weight group
It is grouped as: calcium citrate 143, magnesium carbonate 12, ferrous sulfate 2.8, magnesium chloride 2.5, zinc sulfate 2.3, copper sulphate 0.085, sulfuric acid
Manganese 0.22；The vitamin premix is grouped as by the group of following parts by weight: L-AA 40, L-AA salt 26, day
Right vitamin E 6.8, niacinamide 2.4, D-VB5 calcium 2.2, riboflavin 0.96, thiamine hydrochloride 0.32, puridoxine hydrochloride 0.27,
Axerophtholum aceticum 0.55, folic acid 0.07, phytondione 0.05, biotin 0.01, Vitamin D3 0.01, cyanocobalamin 0.01, chlorine
Change choline 31.5, choline bitartrate 204.
5. such as the described in any item alimentation compositions of Claims 1-4, which is characterized in that the prebiotics are in FOS and GOS
At least one.
6. alimentation composition as claimed in claim 5, which is characterized in that the diet butyric acid is butyric acid, butyrate, includes fourth
At least one of alkyl and/or glyceride, butyric acid-cyclodextrin-complex of acid.
7. alimentation composition as described in claim 1, which is characterized in that the alimentation composition is added to modulation when in use
In milk powder, weight percent of the alimentation composition in modulation milk powder is 7-10%.
8. the application method of alimentation composition as described in claim 1, which is characterized in that the method is to add alimentation composition
It adds in modulation milk powder, weight percent of the alimentation composition in modulation milk powder is 7-10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910384706.5A CN110122881A (en) | 2019-05-09 | 2019-05-09 | A kind of alimentation composition promoting child height development |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910384706.5A CN110122881A (en) | 2019-05-09 | 2019-05-09 | A kind of alimentation composition promoting child height development |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110122881A true CN110122881A (en) | 2019-08-16 |
Family
ID=67576934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910384706.5A Pending CN110122881A (en) | 2019-05-09 | 2019-05-09 | A kind of alimentation composition promoting child height development |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110122881A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110999975A (en) * | 2019-12-19 | 2020-04-14 | 白永纯 | Formula milk powder for promoting bone growth of children and preparation method thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1711859A (en) * | 2005-06-25 | 2005-12-28 | 苟春虎 | Fermented milk sheets with auxin |
| EP2502507A1 (en) * | 2011-03-21 | 2012-09-26 | Abbott Laboratories | Methods for improving bone health in infants using prebiotics |
| CN104206539A (en) * | 2014-08-14 | 2014-12-17 | 澳优乳业（中国）有限公司 | Probiotic-containing infant milk powder |
| CN104351356A (en) * | 2014-11-25 | 2015-02-18 | 澳优乳业（中国）有限公司 | Novel fourth-generation infant formula and preparation method thereof |
| CN107041546A (en) * | 2016-02-05 | 2017-08-15 | 上海他普亚贸易有限公司 | A kind of amino acid formula powder and preparation method thereof |
| CN107712874A (en) * | 2017-10-17 | 2018-02-23 | 天津市德恒科技有限公司 | Depth hydrolysis' protein prescription powder and technique manufacturing method |
| CN107873994A (en) * | 2017-11-20 | 2018-04-06 | 江苏雅博动物健康科技有限责任公司 | One kind promotes bone growth milk powder and preparation method thereof |
| CN108174921A (en) * | 2018-02-08 | 2018-06-19 | 呼伦贝尔双娃乳业有限公司 | A kind of organic babies ' formula milk powder |
| US10039805B1 (en) * | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
| CN108522655A (en) * | 2018-04-13 | 2018-09-14 | 内蒙古欧世蒙牛乳制品有限责任公司 | The baby milk and preparation method of micro functional active components in a kind of across-the-board regulation formula |
| CN109287756A (en) * | 2018-10-12 | 2019-02-01 | 江门市新会区古井源丰资产管理有限公司 | A kind of formula milk |
-
2019
- 2019-05-09 CN CN201910384706.5A patent/CN110122881A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1711859A (en) * | 2005-06-25 | 2005-12-28 | 苟春虎 | Fermented milk sheets with auxin |
| EP2502507A1 (en) * | 2011-03-21 | 2012-09-26 | Abbott Laboratories | Methods for improving bone health in infants using prebiotics |
| CN104206539A (en) * | 2014-08-14 | 2014-12-17 | 澳优乳业（中国）有限公司 | Probiotic-containing infant milk powder |
| CN104351356A (en) * | 2014-11-25 | 2015-02-18 | 澳优乳业（中国）有限公司 | Novel fourth-generation infant formula and preparation method thereof |
| CN107041546A (en) * | 2016-02-05 | 2017-08-15 | 上海他普亚贸易有限公司 | A kind of amino acid formula powder and preparation method thereof |
| US10039805B1 (en) * | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
| CN107712874A (en) * | 2017-10-17 | 2018-02-23 | 天津市德恒科技有限公司 | Depth hydrolysis' protein prescription powder and technique manufacturing method |
| CN107873994A (en) * | 2017-11-20 | 2018-04-06 | 江苏雅博动物健康科技有限责任公司 | One kind promotes bone growth milk powder and preparation method thereof |
| CN108174921A (en) * | 2018-02-08 | 2018-06-19 | 呼伦贝尔双娃乳业有限公司 | A kind of organic babies ' formula milk powder |
| CN108522655A (en) * | 2018-04-13 | 2018-09-14 | 内蒙古欧世蒙牛乳制品有限责任公司 | The baby milk and preparation method of micro functional active components in a kind of across-the-board regulation formula |
| CN109287756A (en) * | 2018-10-12 | 2019-02-01 | 江门市新会区古井源丰资产管理有限公司 | A kind of formula milk |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110999975A (en) * | 2019-12-19 | 2020-04-14 | 白永纯 | Formula milk powder for promoting bone growth of children and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guéguen et al. | The bioavailability of dietary calcium | |
| CA2532472C (en) | Infant or follow-on formula | |
| AU2009306497B2 (en) | Nutritional composition with anti-regurgitation properties | |
| US20110028389A1 (en) | Use of infant formula with reduced protein content | |
| CN111602720A (en) | Formula milk powder for middle-aged and old people | |
| JP2002513544A (en) | Food compositions and uses thereof | |
| Pfeuffer et al. | Nutrition and health aspects of milk and dairy products and their ingredients | |
| CN113647469A (en) | Children formula milk powder for promoting bone growth and preparation method thereof | |
| CN104798908A (en) | Zinc-rich formula goat milk powder and preparation method thereof | |
| CN108576524A (en) | A kind of peracidity sport nutrition liquid and its preparation process | |
| CN107494963B (en) | Calcium paste for pets and preparation method thereof | |
| CN109090443A (en) | It is a kind of to replenish the calcium the nutrition formula product of strong bone function with lock calcium | |
| Pampaloni et al. | Parmigiano Reggiano cheese and bone health | |
| US20050064014A1 (en) | Use of cystathionine | |
| EA011075B1 (en) | Dry powdered milk formula | |
| EA016259B1 (en) | Use of calcium-peptide component for weight reduction | |
| CN104939089B (en) | With alimentation composition for improving bone substance density improving function and preparation method and application | |
| CN110122881A (en) | A kind of alimentation composition promoting child height development | |
| SG172774A1 (en) | Nutritional composition for infants | |
| CN108432880A (en) | A kind of formula milk and preparation method thereof suitable for standby pregnant Mrs phase | |
| CN108497250A (en) | A kind of the lactalbumin sports drink and production technology of MCT reinforcings | |
| CN106417619A (en) | Milk calcium powder for promoting skeleton growth and enhancing immunity | |
| US20090258833A1 (en) | Fortified liquid protein compositions and methods of making same | |
| JP2016506753A (en) | Food composition and use thereof | |
| CN112262993A (en) | Composite polypeptide calcium powder and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |